Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 9/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375950 | 0.82 | AGPAT2 (0.78) | AGPAT2ALDH1A1 | |
| SCHEMBL14439011 | 0.80 | AGPAT2 (1.00) | AGPAT2ALDH1A1 | |
| SCHEMBL5375776 | 0.79 | AGPAT2 (0.80) | AGPAT2ALDH1A1 | |
| SCHEMBL14439009 | 0.77 | AGPAT2 (1.00) | AGPAT2ALDH1A1 | |
| SCHEMBL5380261 | 0.75 | AGPAT2 (0.76) | AGPAT2ALDH1A1 | |
| SCHEMBL13880180 | 0.74 | AGPAT2 (0.88) | AGPAT2 | |
| SCHEMBL14439012 | 0.73 | AGPAT2 (1.00) | AGPAT2ALDH1A1 | |
| SCHEMBL4286837 | 0.71 | AGPAT2 (0.75) | AGPAT2MAPT | |
| SCHEMBL14439010 | 0.70 | AGPAT2 (1.00) | AGPAT2ALDH1A1 | |
| SCHEMBL11515491 | 0.70 | ALDH1A1 (0.82) | ALDH1A1LMNANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050182102-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6875781-B2 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040198728-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198728-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 23/4885ADORA3 1956/4885ALDH1A1 884/4885 |
| US-20070178134-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885ADORA3 1801/4885ALDH1A1 728/4885 |
| US-20050182102-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885ADORA3 1801/4885ALDH1A1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.